Table 2.

AGE immunolocalization in diabetic nephropathy versus nondiabetic renal diseases^a

	AGE Immunolocalization (%)^b
	Sclerotic Glomeruli		GBM		Mesangium		TBM		Interstitium		Vessels
	CML	PENT	CML	PENT	CML	PENT	CML	PENT	CML	PENT	CML	PENT
^aAGE, advanced glycation end products; FSGS, focal segmental glomerulosclerosis.
^bExpressed as percentage of cases with any positive immunostaining.
^cExpressed as percentage of cases with 2+ or 3+ immunostaining.
Diabetic nephropathy	94.4	87.8	42.3	3.9	96.2	76.9	84.6	30.8	15.4	92.3	96.2	53.9
Primary FSGS	71.4	100.0	50.0	10.0	20.0	40.0	30.0	50.0	10.0	70.0	40.0	30.0
Secondary FSGS	40.0	60.0	0.0	0.0	14.3	85.7	14.3	0.0	14.3	28.6	28.6	14.3
Hypertensive nephrosclerosis	100.0	71.4	42.9	0.0	28.6	28.6	85.7	28.6	42.9	57.1	100.0	85.7
Lupus nephritis	80.0	60.0	54.5	45.5	27.3	63.6	27.3	36.4	0.0	90.9	54.5	18.2
	AGE Immunolocalization (%)^c
	Sclerotic Glomeruli		GBM		Mesangium		TBM		Interstitium		Vessels
	CML	PENT	CML	PENT	CML	PENT	CML	PENT	CML	PENT	CML	PENT
Diabetic nephropathy	77.8	55.6	18.2	3.9	30.8	30.8	53.8	11.5	3.9	61.5	80.8	19.2
Primary FSGS	14.3	100.0	0.0	0.0	0.0	0.0	10.0	30.0	10.0	30.0	30.0	10.0
Secondary FSGS	20.0	40.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Hypertensive nephrosclerosis	57.1	71.4	0.0	0.0	0.0	0.0	28.6	28.6	0.0	28.6	100.0	28.6
Lupus nephritis	60.0	40.0	9.1	27.3	9.1	18.2	0.0	18.2	0.0	27.3	18.2	9.1